DUBLIN, Ireland, Sept. 11, 2017 -- Horizon Pharma plc (NASDAQ:HZNP), a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today named Irina Konstantinovsky executive vice president, chief human resources officer, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately.
“Irina is an accomplished human resources professional with an excellent track record of attracting, developing and retaining talent as well as building an inclusive and engaging culture,” said Walbert. “Her extensive experience will be critical as the company continues to grow and evolve.”
Prior to Horizon, Konstantinovsky was vice president of global talent at Baxter International Inc. where she led a team of talent professionals worldwide and oversaw organizational effectiveness, leadership development, inclusion and diversity and talent acquisition. She and her team were responsible for talent management strategies, programs and systems for more than 50,000 employees worldwide.
“Horizon Pharma has a strong, patient-centered culture with passionate, committed employees at its core,” said Konstantinovsky. “I’m looking forward to helping build a world-class human resources function that continues to foster and develop these strengths.”
Prior to Baxter, Konstantinovsky spent 15 years in senior partner and director roles at Towers Watson (currently Willis Towers Watson), a global human resources consulting firm serving Fortune 1000 companies. While in these roles, she served as the interim chief human resource officer at Capital BlueCross for two years.
She has a Bachelor of Arts in Education from the University of Buenos Aires and master’s degrees in higher education and industrial and labor relations from Cornell University. In addition, Konstantinovsky serves on the board of the Human Resource Management Association of Chicago.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]


First Western Ship Transits Strait of Hormuz Since Iran War Began
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 



